Last Updated: August 13, 2026

Litigation Details for United Therapeutics Corporation v. Liquidia Technologies, Inc. (D. Del. 2023)

✉ Email this page to a colleague

« Back to Dashboard

United Therapeutics Corporation v. Liquidia Technologies, Inc. (D. Del. 2023)

Docket	⤷ Start Trial	Date Filed	2023-09-05
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To	Sherry R. Fallon
Parties	UNITED THERAPEUTICS CORPORATION
Patents	10,029,010; 10,030,005; 10,039,745; 10,072,013; 10,086,011; 10,154,987; 10,183,003; 10,183,012; 10,183,020; 10,220,023; 10,376,525; 10,716,793; 10,786,482; 10,828,310; 11,723,887; 11,826,327; 11,879,013; 11,975,001; 12,013,403; 12,023,325; 12,128,021; 12,168,015; 12,168,016; 12,194,005; 12,247,012; 6,011,068; 6,028,222; 6,521,212; 6,720,001; 6,756,033; 6,765,117; 6,977,257; 7,417,070; 7,544,713; 7,967,011; 7,999,007; 8,013,002; 8,017,150; 8,106,021; 8,217,007; 8,252,839; 8,349,892; 8,410,169; 8,497,393; 8,568,747; 8,653,137; 8,658,694; 8,747,897; 8,778,366; 8,927,010; 9,024,007; 9,050,311; 9,062,014; 9,127,013; 9,199,908; 9,200,002; 9,278,901; 9,339,507; 9,358,240; 9,422,223; 9,463,183; 9,562,017; 9,593,066; 9,604,901; 9,623,001; 9,623,022; 9,669,008; 9,764,003; 9,808,442; 9,855,214; 9,919,024; 9,968,553
Attorneys	Rachel L. Preston
Firms	Shaw Keller LLP
Link to Docket	External link to docket

Small Molecule Drugs cited in United Therapeutics Corporation v. Liquidia Technologies, Inc.

The small molecule drugs covered by the patents cited in this case are ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , and ⤷ Start Trial .

Details for United Therapeutics Corporation v. Liquidia Technologies, Inc. (D. Del. 2023)

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Date Filed	Document No.	Description	Snippet	Link To Document
2023-09-05				External link to document
2023-09-05	127	Redacted Document	LIQ_PH-ILD_00101827) 14 \| US. Patent No. 9,339,507 (LIQ_PH-ILD_00101803) 15 \| USS. Patent No. 10,376,525 (LIQ_PH-ILD…Ex. 13 (U.S. Patent No. 9,358,240) at 12:49-50 (same); Ex. 14 (U.S. Patent No. 9,339,507) at 12:57-5S8…7:18—22; Ex. 14 (U.S. Patent No. 9,339,507) at 7:18—22; Ex. 15 (U.S. Patent No. 10,376,525) at 7:18—22…0200449 and U.S. Patent Nos. 9,358,240; 9,339,507; 10,376,525; and 10,716,793 as examples of pulsed inhalation…asserted two patents, only one is at issue in this case—U.S. Patent No. 11,826,327 (the “’327 patent”). To justify	External link to document
2023-09-05	71	Redacted Document	]. US Patent No. 5,153,222 US Patent No. 6,765,117 US Patent No. 6,521,212 US Patent No. 6,756,… a) The ’212 patent U.S. Patent No. 6,521,212 (“the ’212 patent”) issued February 8…United States Patent 67 No. 6,521,212 B1 16 … 6,521,212 Bl 2/2003 Gilles et al. (65) …preparation of the pharmacologically active 6,521,212 and 6,756,033 describe administration of trepro	External link to document
2023-09-05	94	Claim Construction Chart	9,339,507 …Construction Chart (Ex. A) for U.S. Patent No. 11,826,327 (“the ’327 patent”) (Ex. B). Exhibit A includes…adverse ’327 Patent Prosecution indefiniteness under § ʼ327 patent at: … is into ’327 patent by Liquidia’s device does ʼ327 patent: … claims into ’327 patent by ʼ327 patent:	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.